- Guideline/Fact Sheet
- 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
-
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae Jin Kim, Hyun Min Kim, Jung Hae Ko, Nam Hoon Kim, Chong Hwa Kim, Jeeyun Ahn, Tae Jung Oh, Soo-Kyung Kim, Jaehyun Kim, Eugene Han, Sang-Man Jin, Jaehyun Bae, Eonju Jeon, Ji Min Kim, Seon Mee Kang, Jung Hwan Park, Jae-Seung Yun, Bong-Soo Cha, Min Kyong Moon, Byung-Wan Lee
-
Diabetes Metab J. 2024;48(4):546-708. Published online July 26, 2024
-
DOI: https://doi.org/10.4093/dmj.2024.0249
-
-
5,418
View
-
362
Download
-
3
Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by
- Adherence to the nutritional recommendations according to diabetes status in Korean adults: a cross-sectional study
Jong Han Choi, Chen Lulu, Seon-Joo Park, Hae-Jeung Lee BMC Public Health.2024;[Epub] CrossRef - 당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
종한 최, 민경 문 Public Health Weekly Report.2024; 17(44): 1905. CrossRef - The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Case–Control Study and a Prospective Study
Ga Hyun Lee, Yeon Hee Kim, Sang Myung Woo, Woo Jin Lee, Sung-Sik Han, Sang-Jae Park, Sherry Price, Penias Tembo, James R. Hébert, Mi Kyung Kim Nutrients.2024; 16(22): 3941. CrossRef
- Drug/Regimen
- Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
-
Ji Hye Han, Kyong Hye Joung, Jun Choul Lee, Ok Soon Kim, Sorim Choung, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Bon Jeong Ku, Hyun Jin Kim
-
Diabetes Metab J. 2024;48(1):112-121. Published online January 3, 2024
-
DOI: https://doi.org/10.4093/dmj.2022.0402
-
-
4,870
View
-
410
Download
-
4
Web of Science
-
4
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid profile, insulin sensitivity, and vascular inflammatory response in patients with T2DM.
Methods A total of 101 patients with T2DM and dyslipidemia were randomized to either rosuvastatin monotherapy (5 mg/day, n=47) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day, n=45) and treated for 12 weeks. Serum lipids, glucose, insulin, soluble intercellular adhesion molecule-1 (sICAM-1), and peroxiredoxin 4 (PRDX4) levels were determined before and after 12 weeks of treatment.
Results The reduction in low density lipoprotein cholesterol (LDL-C) by more than 50% from baseline after treatment was more in the combination therapy group. The serum sICAM-1 levels increased significantly in both groups, but there was no difference between the two groups. The significant changes in homeostasis model assessment of insulin resistance (HOMA-IR) and PRDX4 were confirmed only in the subgroup in which LDL-C was reduced by 50% or more in the combination therapy group. However, after adjusting for diabetes mellitus duration and hypertension, the changes in HOMA-IR and PRDX4 were not significant between the two groups.
Conclusion Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.
-
Citations
Citations to this article as recorded by
- Combining Ezetimibe and Rosuvastatin: Impacts on Insulin Sensitivity and Vascular Inflammation in Patients with Type 2 Diabetes Mellitus
Eun Roh Diabetes & Metabolism Journal.2024; 48(1): 55. CrossRef - Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?
Il Rae Park, Jun Sung Moon Diabetes & Metabolism Journal.2024; 48(3): 387. CrossRef - A Comparison of Rosuvastatin Monotherapy and Rosuvastatin Plus Ezetimibe Combination Therapy in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Samuel K Dadzie, Godfrey Tabowei, Mandeep Kaur, Saeed Ahmed, Aayushi Thakur, Khaldoun Khreis, Monika Bai, Adil Amin Cureus.2024;[Epub] CrossRef - The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaos Tentolouris, Natalia G. Vallianou, Iordanis Mourouzis, Irene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha, Maria Dalamaga Metabolites.2024; 14(7): 388. CrossRef
- Guideline/Fact Sheet
- 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
-
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae Jin Kim, Hyun Min Kim, Jung Hae Ko, Nam Hoon Kim, Chong Hwa Kim, Jeeyun Ahn, Tae Jung Oh, Soo-Kyung Kim, Jaehyun Kim, Eugene Han, Sang-Man Jin, Won Suk Choi, Min Kyong Moon, Committee of Clinical Practice Guidelines, Korean Diabetes Association
-
Diabetes Metab J. 2023;47(5):575-594. Published online September 26, 2023
-
DOI: https://doi.org/10.4093/dmj.2023.0282
-
-
10,846
View
-
1,175
Download
-
31
Web of Science
-
39
Crossref
-
Abstract
PDFPubReader ePub
- In May 2023, the Committee of Clinical Practice Guidelines of the Korean Diabetes Association published the revised clinical practice guidelines for Korean adults with diabetes and prediabetes. We incorporated the latest clinical research findings through a comprehensive systematic literature review and applied them in a manner suitable for the Korean population. These guidelines are designed for all healthcare providers nationwide, including physicians, diabetes experts, and certified diabetes educators who manage patients with diabetes or individuals at risk of developing diabetes. Based on recent changes in international guidelines and the results of a Korean epidemiological study, the recommended age for diabetes screening has been lowered. In collaboration with the relevant Korean medical societies, recently revised guidelines for managing hypertension and dyslipidemia in patients with diabetes have been incorporated into this guideline. An abridgment containing practical information on patient education and systematic management in the clinic was published separately.
-
Citations
Citations to this article as recorded by
- Management of Elderly Patients with Chronic Kidney Disease
Yohan Park, Won Min Hwang Yonsei Medical Journal.2025;[Epub] CrossRef - Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim Metabolism.2024; 152: 155789. CrossRef - Letter by In-Kyung Jeong Regarding Article, Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study
In-Kyung Jeong Journal of Lipid and Atherosclerosis.2024; 13(1): 80. CrossRef - Association between cardiovascular disease risk and incident type 2 diabetes mellitus in individuals with prediabetes: A retrospective cohort study
Myung Jin Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee Diabetes Research and Clinical Practice.2024; 208: 111125. CrossRef - Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
Hyeon Chang Kim, Hokyou Lee, Hyeok-Hee Lee, Dasom Son, Minsung Cho, Sojung Shin, Yeeun Seo, Eun-Jin kim, Song Vogue Ahn, Sun Ha Jee, Sungha Park, Hae-Young Lee, Min Ho Shin, Sang-Hyun Ihm, Seung Won Lee, Jong Ku Park, Il Suh, Tae-Yong Lee Clinical Hypertension.2024;[Epub] CrossRef - Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2317. CrossRef - Effect of Adding Apolipoprotein B Testing on the Prevalence of Dyslipidemia and Risk of Cardiovascular Disease in the Korean Adult Population
Rihwa Choi, Sang Gon Lee, Eun Hee Lee Metabolites.2024; 14(3): 169. CrossRef - Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT
Eu Jeong Ku, Bongseong Kim, Kyungdo Han, Seung-Hwan Lee, Hyuk-Sang Kwon Cardiovascular Diabetology.2024;[Epub] CrossRef - A self-powered and supercapacitive microneedle continuous glucose monitoring system with a wide range of glucose detection capabilities
Hye-Jun Kil, Jang Hyeon Kim, Kanghae Lee, Tae-Uk Kang, Ju-Hyun Yoo, Yong-ho Lee, Jin-Woo Park Biosensors and Bioelectronics.2024; 257: 116297. CrossRef - Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history
Jin Hwa Kim, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon Diabetes, Obesity and Metabolism.2024; 26(7): 2567. CrossRef - SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong Scientific Reports.2024;[Epub] CrossRef - The importance of diabetes mellitus in dental practice
Nina Dimitrijević-Jovanović, Hristina Ugrinović, Radomir Mitić, Nevena Kalezić Galenika Medical Journal.2024; 3(9): 80. CrossRef - Evaluation of glycemic response of ten local meals commonly consumed from Chad
Zoufane Guedeungbe, Jean Paul Bayang, Benoît Bargui Koubala Journal of Agriculture and Food Research.2024; 17: 101251. CrossRef - Glycemic Control and Oral Health Outcomes in Patients With Diabetes: Insights From a Nationwide Korean Survey
Song-Yi Yu, Sun-Kyung Lee, Bumhee Yang, Hyun Lee, Hyun Jeong Jeon, Dong-Hwa Lee Journal of Korean Medical Science.2024;[Epub] CrossRef - Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Rajiv Singla, Sanjay Kalra Medicine.2024; 103(25): e38568. CrossRef - Longitudinal Analysis of Diabetes Mellitus Risk: Smoking Status and Smoking Cessation
Da-Eun Sung, Seung-Jae Lee, Mi-Yeon Lee, Eun-Jung Rhee, Ki-Chul Sung Journal of Clinical Medicine.2024; 13(13): 3927. CrossRef - Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Juliana C. N. Chan, Aimin Yang, Natural Chu, Elaine Chow Diabetes, Obesity and Metabolism.2024; 26(S3): 55. CrossRef - Comprehensive management of polypharmacy in older patients with diabetes
Kang Seo Park, Hea Min Yu Journal of the Korean Medical Association.2024; 67(7): 449. CrossRef - The Key Role of Nutritional Intervention in Delaying Disease Progression and the Therapeutic Management of Diabetic Kidney Disease—A Challenge for Physicians and Patients
Ileana Peride, Miruna Anastasiu, Silvia Alexandra Serban, Mirela Tiglis, Razvan Ene, Ana-Maria Nechita, Tiberiu Paul Neagu, Ionel Alexandru Checherita, Andrei Niculae Journal of Personalized Medicine.2024; 14(8): 778. CrossRef - Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study
Yun Kyung Cho, Kyung-Soo Kim, Byung-Wan Lee, Jun Hwa Hong, Jae Myung Yu, Soo Lim, Ye An Kim, Chang Beom Lee, Sang Soo Kim, Soo Heon Kwak, Woo Je Lee Clinical Therapeutics.2024; 46(9): 662. CrossRef - Islet transplantation in Korea
Joonyub Lee, Kun‐Ho Yoon Journal of Diabetes Investigation.2024; 15(9): 1165. CrossRef - Effect of gout and diabetic kidney disease on renal cancer development in Korea
Seung Min Chung, Inha Jung, Da Young Lee, So Young Park, Ji Hee Yu, Jun Sung Moon, Ji A Seo, Kyungdo Han, Nan Hee Kim Clinical Kidney Journal.2024;[Epub] CrossRef - Cardiovascular autonomic neuropathy and the risk of diabetic kidney disease
Injeong Cho, Seohyun Lim, Minjae Kwon, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won Frontiers in Endocrinology.2024;[Epub] CrossRef - Educational Needs and Priorities of People with Diabetes and Healthcare Providers in South Korea: A Mixed-Methods Study
Shinae Seo, Chun-Ja Kim, Hee Sun Kang, Elizabeth A. Schlenk Journal of Transcultural Nursing.2024;[Epub] CrossRef - Changes in serum uteroglobin level in type 2 diabetes mellitus patients
Joung Youl Lim, Sang-Hyeon Ju, Ji Min Kim, Hyon-Seung Yi, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku, Kyong Hye Joung Frontiers in Endocrinology.2024;[Epub] CrossRef - Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin (AJU‐A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
Jun Hwa Hong, Myung Jin Kim, Kyung Wan Min, Jong Chul Won, Tae Nyun Kim, Byung‐Wan Lee, Jun Goo Kang, Jae Hyeon Kim, Jung Hwan Park, Bon Jeong Ku, Chang Beom Lee, Sang Yong Kim, Ho Sang Shon, Woo Je Lee, Joong‐Yeol Park Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef - 1-Hour Postload Glucose: Early Screening for High Risk of Type 2 Diabetes in Koreans With Normal Fasting Glucose
Min Jin Lee, Ji Hyun Bae, Ah Reum Khang, Dongwon Yi, Joo Yeon Kim, Su Hyun Kim, Dong Hee Kim, Dasol Kang, Sujin Park, Yun Kyung Jeon, Sang Soo Kim, Bo Hyun Kim, Mi Sook Yun, Yang Ho Kang The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef - Sodium-glucose cotransporter 2 inhibitors in cardiocerebrovascular disease
Jin Joo Park Cardiovascular Prevention and Pharmacotherapy.2024; 6(4): 103. CrossRef - Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus
Jennifer Bolt, Valeria Carvalho, Kristine Lin, Sung Ju Lee, Colleen Inglis Age and Ageing.2024;[Epub] CrossRef - Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim Journal of Diabetes Investigation.2024;[Epub] CrossRef - Socioeconomic inequalities in the prevalence, non-awareness, non-treatment, and non-control of diabetes among South Korean adults in 2021
Seongju Kim, Dong Jun Kim, Hooyeon Lee, Dong Keon Yon PLOS ONE.2024; 19(11): e0313988. CrossRef - Association of Uterine Leiomyoma with Type 2 Diabetes Mellitus in Young Women: A Population-Based Cohort Study
Ji-Hee Sung, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park Diabetes & Metabolism Journal.2024; 48(6): 1105. CrossRef - Combined impact of prediabetes and hepatic steatosis on cardiometabolic outcomes in young adults
Wonsuk Choi, Minae Park, Sojeong Park, Ji Yong Park, A Ram Hong, Jee Hee Yoon, Kyoung Hwa Ha, Dae Jung Kim, Hee Kyung Kim, Ho-Cheol Kang Cardiovascular Diabetology.2024;[Epub] CrossRef - Management of Dyslipidemia in Patients with Diabetes Mellitus
Kyung Ae Lee The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef - 2023 Clinical Practice Guidelines for Diabetes: Recommendations for Pharmacological Treatment of Type 2 Diabetes
Junghyun Noh The Journal of Korean Diabetes.2023; 24(3): 127. CrossRef - 2023 Clinical Practice Guidelines for Diabetes
Min Kyong Moon The Journal of Korean Diabetes.2023; 24(3): 120. CrossRef - 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
Ye Seul Yang The Journal of Korean Diabetes.2023; 24(3): 135. CrossRef - A 33-Year-Old Man Presented with Abdominal Pain and Vomiting Starting a Day Ago
Jong Han Choi The Korean Journal of Medicine.2023; 98(6): 289. CrossRef - Comorbidity Patterns and Management in Inpatients with Endocrine Diseases by Age Groups in South Korea: Nationwide Data
Sung-Soo Kim, Hun-Sung Kim Journal of Personalized Medicine.2023; 14(1): 42. CrossRef
- Drug/Regimen
- Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study)
-
Ji Cheol Bae, Soo Heon Kwak, Hyun Jin Kim, Sang-Yong Kim, You-Cheol Hwang, Sunghwan Suh, Bok Jin Hyun, Ji Eun Cha, Jong Chul Won, Jae Hyeon Kim
-
Diabetes Metab J. 2022;46(1):81-92. Published online June 16, 2021
-
DOI: https://doi.org/10.4093/dmj.2021.0016
-
-
9,061
View
-
459
Download
-
5
Web of Science
-
5
Crossref
-
Graphical Abstract
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
To evaluate the effects of teneligliptin on glycosylated hemoglobin (HbA1c) levels, continuous glucose monitoring (CGM)-derived time in range, and glycemic variability in elderly type 2 diabetes mellitus patients.
Methods This randomized, double-blinded, placebo-controlled study was conducted in eight centers in Korea (clinical trial registration number: NCT03508323). Sixty-five participants aged ≥65 years, who were treatment-naïve or had been treated with stable doses of metformin, were randomized at a 1:1 ratio to receive 20 mg of teneligliptin (n=35) or placebo (n=30) for 12 weeks. The main endpoints were the changes in HbA1c levels from baseline to week 12, CGM metrics-derived time in range, and glycemic variability.
Results After 12 weeks, a significant reduction (by 0.84%) in HbA1c levels was observed in the teneligliptin group compared to that in the placebo group (by 0.08%), with a between-group least squares mean difference of –0.76% (95% confidence interval [CI], –1.08 to –0.44). The coefficient of variation, standard deviation, and mean amplitude of glycemic excursion significantly decreased in participants treated with teneligliptin as compared to those in the placebo group. Teneligliptin treatment significantly decreased the time spent above 180 or 250 mg/dL, respectively, without increasing the time spent below 70 mg/dL. The mean percentage of time for which glucose levels remained in the 70 to 180 mg/dL time in range (TIR70–180) at week 12 was 82.0%±16.0% in the teneligliptin group, and placebo-adjusted change in TIR70–180 from baseline was 13.3% (95% CI, 6.0 to 20.6).
Conclusion Teneligliptin effectively reduced HbA1c levels, time spent above the target range, and glycemic variability, without increasing hypoglycemia in our study population.
-
Citations
Citations to this article as recorded by
- Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study
Harmanjit Singh, Ravi Rohilla, Shivani Jaswal, Mandeep Singla Expert Review of Endocrinology & Metabolism.2024; 19(1): 81. CrossRef - Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh, Farideh Javid Expert Review of Clinical Pharmacology.2023; 16(1): 49. CrossRef - Mechanism of molecular interaction of sitagliptin with human DPP4 enzyme - New Insights
Michelangelo Bauwelz Gonzatti, José Edvar Monteiro Júnior, Antônio José Rocha, Jonathas Sales de Oliveira, Antônio José de Jesus Evangelista, Fátima Morgana Pio Fonseca, Vânia Marilande Ceccatto, Ariclécio Cunha de Oliveira, José Ednésio da Cruz Freire Advances in Medical Sciences.2023; 68(2): 402. CrossRef - A prospective multicentre open label study to assess effect of Teneligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study)
Banshi Saboo, Suhas Erande, A.G. Unnikrishnan Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(2): 102394. CrossRef - Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes
Min Jeong Park, Kyung Mook Choi Diabetes & Metabolism Journal.2022; 46(1): 49. CrossRef
- Pathophysiology
- Regulation of Systemic Glucose Homeostasis by T Helper Type 2 Cytokines
-
Yea Eun Kang, Hyun Jin Kim, Minho Shong
-
Diabetes Metab J. 2019;43(5):549-559. Published online October 24, 2019
-
DOI: https://doi.org/10.4093/dmj.2019.0157
-
-
7,774
View
-
105
Download
-
10
Web of Science
-
10
Crossref
-
Abstract
PDFPubReader
Obesity results in an inflammatory microenvironment in adipose tissue, leading to the deterioration of tissue protective mechanisms. Although recent studies suggested the importance of type 2 immunity in an anti-inflammatory microenvironment in adipose tissue, the regulatory effects of T helper 2 (Th2) cytokines on systemic metabolic regulation are not fully understood. Recently, we identified the roles of the Th2 cytokine (interleukin 4 [IL-4] and IL-13)-induced adipokine, growth differentiation factor 15 (GDF15), in adipose tissue in regulating systemic glucose metabolism via signal transducer and activator of transcription 6 (STAT6) activation. Moreover, we showed that mitochondrial oxidative phosphorylation is required to maintain these macrophage-regulating autocrine and paracrine signaling pathways via Th2 cytokine-induced secretion of GDF15. In this review, we discuss how the type 2 immune response and Th2 cytokines regulate metabolism in adipose tissue. Specifically, we review the systemic regulatory roles of Th2 cytokines in metabolic disease and the role of mitochondria in maintenance of type 2 responses in adipose tissue homeostasis.
-
Citations
Citations to this article as recorded by
- Orchestration of the Adipose Tissue Immune Landscape by Adipocytes
David Bradley, Tuo Deng, Dharti Shantaram, Willa A. Hsueh Annual Review of Physiology.2024; 86(1): 199. CrossRef - Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease
Balázs Bence Nyárády, Loretta Zsuzsa Kiss, Zsolt Bagyura, Béla Merkely, Edit Dósa, Orsolya Láng, László Kőhidai, Éva Pállinger Biomedicine & Pharmacotherapy.2024; 174: 116475. CrossRef - Evaluation of Mitochondrial Function in Blood Samples Shows Distinct Patterns in Subjects with Thyroid Carcinoma from Those with Hyperplasia
Julia Bernal-Tirapo, María Teresa Bayo Jiménez, Pedro Yuste-García, Isabel Cordova, Ana Peñas, Francisco-Javier García-Borda, Cesar Quintela, Ignacio Prieto, Cristina Sánchez-Ramos, Eduardo Ferrero-Herrero, María Monsalve International Journal of Molecular Sciences.2023; 24(7): 6453. CrossRef - A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome
Ronit Vogt Sionov, Ronit Ahdut-HaCohen Biomedicines.2023; 11(9): 2558. CrossRef - Gdf15 deletion exacerbates acute lung injuries induced by intratracheal inoculation of aerosolized ricin in mice
Mengyun Deng, Duo Su, Nan Xiao, Zhipeng Zhang, Yifeng Wang, Fuliang Zong, Sha Li, Jinglin Wang, Dongsheng Zhou, Yuee Zhao, Huiying Yang Toxicology.2022; 469: 153135. CrossRef - Role of PPAR Receptor and Ligands in the Pathogenesis and Therapy of Hematologic Malignancies
Jian Wu, Min Zhang, Allison Faircloth Hemato.2022; 3(3): 422. CrossRef - Macrophage and Adipocyte Mitochondrial Dysfunction in Obesity-Induced Metabolic Diseases
Liwen Wang, Jie Hu, Haiyan Zhou The World Journal of Men's Health.2021; 39(4): 606. CrossRef - Th2 Cytokines Increase the Expression of Fibroblast Growth Factor 21 in the Liver
Seul-Gi Kang, Seong-Eun Lee, Min-Jeong Choi, Joon-Young Chang, Jung-Tae Kim, Ben-Yuan Zhang, Yea-Eun Kang, Ju-Hee Lee, Hyon-Seung Yi, Minho Shong Cells.2021; 10(6): 1298. CrossRef - Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
Jörg Wischhusen, Ignacio Melero, Wolf Herman Fridman Frontiers in Immunology.2020;[Epub] CrossRef - Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
Irina Larionova, Elena Kazakova, Marina Patysheva, Julia Kzhyshkowska Cancers.2020; 12(6): 1411. CrossRef
- Others
- Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance
-
Yea Eun Kang, Ji Min Kim, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
-
Diabetes Metab J. 2019;43(3):368-376. Published online October 23, 2018
-
DOI: https://doi.org/10.4093/dmj.2018.0066
-
-
5,833
View
-
82
Download
-
6
Web of Science
-
9
Crossref
-
Abstract
PDFPubReader
- Background
Recent in vivo studies indicated that R-spondin 1 (RSPO1) regulates food intake and increases insulin secretion, but its role in humans remains unknown. This study investigated the association between serum levels of RSPO1 and diverse metabolic parameters in humans. MethodsThe study population consisted of 43 subjects with newly diagnosed diabetes mellitus, and 79 non-diabetic participants. Serum levels of RSPO1 were measured using the enzyme-linked immunosorbent assay. The relationships between circulating RSPO1 and diverse metabolic parameters were analyzed. ResultsCirculating RSPO1 levels increased to a greater extent in the obese group than in the lean group. Moreover, serum levels of RSPO1 were higher in the insulin-resistant group than in the insulin-sensitive group. Serum levels of RSPO1 were significantly correlated with a range of metabolic parameters including body mass index, fasting C-peptide, homeostasis model assessment of insulin resistance index, and lipid profile. Moreover, levels were significantly associated with insulin resistance and obesity in non-diabetic subjects. ConclusionThis study demonstrated the association between serum levels of RSPO1 and a range of metabolic parameters in humans. Serum levels of RSPO1 are significantly related to obesity and insulin resistance, although the precise mechanisms remain unknown.
-
Citations
Citations to this article as recorded by
- Systems genetics analysis of human body fat distribution genes identifies adipocyte processes
Jordan N Reed, Jiansheng Huang, Yong Li, Lijiang Ma, Dhanush Banka, Martin Wabitsch, Tianfang Wang, Wen Ding, Johan LM Björkegren, Mete Civelek Life Science Alliance.2024; 7(7): e202402603. CrossRef - LGR4: A New Receptor Member in Endocrine and Metabolic Diseases
Ningning Zhang, Mingyang Yuan, Jiqiu Wang Endocrine Reviews.2023; 44(4): 647. CrossRef - R-Spondin1 and tumor necrosis factor-alpha in infertile women with polycystic ovary syndrome: relationships with insulin resistance and other parameters
Tuğba GÜRBÜZ, Oya GÖKMEN, Asena AYAR MADENLİ, Berna DİLBAZ Journal of Health Sciences and Medicine.2023; 6(2): 449. CrossRef - An early prediction model for type 2 diabetes mellitus based on genetic variants and nongenetic risk factors in a Han Chinese cohort
Jinjin Li, Qun Ye, Hongxiao Jiao, Wanyao Wang, Kai Zhang, Chen Chen, Yuan Zhang, Shuzhi Feng, Ximo Wang, Yubao Chen, Huailin Gao, Fengjiang Wei, Wei-Dong Li Frontiers in Endocrinology.2023;[Epub] CrossRef - Emerging Therapeutic Strategies for Attenuating Tubular EMT and Kidney Fibrosis by Targeting Wnt/β-Catenin Signaling
Lichao Hu, Mengyuan Ding, Weichun He Frontiers in Pharmacology.2022;[Epub] CrossRef - Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?
Osman BAŞPINAR, Yasin ŞİMŞEK, Derya KOÇER, Oğuzhan Sıtkı DİZDAR, Hatice KAYIŞ TOPALOĞLU Genel Tıp Dergisi.2022; 32(5): 490. CrossRef - Silencing of RSPO1 mitigates obesity-related renal fibrosis in mice by deactivating Wnt/β-catenin pathway
Xuesong Su, Guangyu Zhou, Mi Tian, Si Wu, Yanqiu Wang Experimental Cell Research.2021; 405(2): 112713. CrossRef - Exosome miR‐27a‐3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma
Xuehan Fan, Jingya Wang, Tingting Qin, Yujia Zhang, Wenting Liu, Kaiting Jiang, Dingzhi Huang Thoracic Cancer.2020; 11(6): 1453. CrossRef - Integrative Analyses of Genes Associated with Subcutaneous Insulin Resistance
Manoj Kumar Pujar, Basavaraj Vastrad, Chanabasayya Vastrad Biomolecules.2019; 9(2): 37. CrossRef
- Others
- Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus
-
Ji Min Kim, Sorim Choung, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
-
Diabetes Metab J. 2018;42(4):343-347. Published online May 2, 2018
-
DOI: https://doi.org/10.4093/dmj.2017.0082
-
-
4,914
View
-
56
Download
-
6
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader
We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum sEGFR was positively correlated with glycosylated hemoglobin and serum glucose and negatively correlated with serum insulin and C-peptide levels.
-
Citations
Citations to this article as recorded by
- Increased serum extrachromosomal circular DNA SORBS1circle level is associated with insulin resistance in patients with newly diagnosed type 2 diabetes mellitus
Xiang Kong, Shu-jun Wan, Tian-bing Chen, Lan Jiang, Yu-jie Xing, Ya-ping Bai, Qiang Hua, Xin-ming Yao, Yong-li Zhao, Hong-mei Zhang, De-guo Wang, Qing Su, Kun Lv Cellular & Molecular Biology Letters.2024;[Epub] CrossRef - A Pilot Genome-Wide Association Study Identifies Novel Markers of Metabolic Syndrome in Patients with Psoriasis
Seung-Min Oh, Su-Kang Kim, Hye-Jin Ahn, Ki-Heon Jeong Annals of Dermatology.2023; 35(4): 285. CrossRef - Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia
Jun Choul Lee, Kyong Hye Joung, Ji Min Kim, Seon Mee Kang, Hyun Jin Kim, Bon Jeong Ku Medicine.2022; 101(34): e30287. CrossRef - Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects
Mayu Kyohara, Jun Shirakawa, Tomoko Okuyama, Yu Togashi, Ryota Inoue, Jinghe Li, Daisuke Miyashita, Yasuo Terauchi Diabetology & Metabolic Syndrome.2020;[Epub] CrossRef - Epidermal growth factor protects against myocardial ischaemia reperfusion injury through activating Nrf2 signalling pathway
Jun Ma, Ge Jin Free Radical Research.2019; 53(3): 313. CrossRef
- Epidemiology
- Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index
-
Kyoung Hwa Ha, Cheol Young Park, In Kyung Jeong, Hyun Jin Kim, Sang-Yong Kim, Won Jun Kim, Ji Sung Yoon, In Joo Kim, Dae Jung Kim, Sungrae Kim
-
Diabetes Metab J. 2018;42(2):137-146. Published online February 14, 2018
-
DOI: https://doi.org/10.4093/dmj.2018.42.2.137
-
-
6,146
View
-
91
Download
-
13
Web of Science
-
13
Crossref
-
Abstract
PDFPubReader
- Background
We evaluated the clinical characteristics of insulin resistance and β-cell dysfunction in newly diagnosed, drug-naive people with type 2 diabetes by analyzing nationwide cross-sectional data. MethodsWe collected the clinical data of 912 participants with newly diagnosed diabetes from 83 primary care clinics and hospitals nationwide from 2015 to 2016. The presence of insulin resistance and β-cell dysfunction was defined as a homeostatic model assessment of insulin resistance (HOMA-IR) value ≥2.5 and fasting C-peptide levels <1.70 ng/mL, respectively. ResultsA total of 75.1% and 22.6% of participants had insulin resistance and β-cell dysfunction, respectively. The proportion of participants with insulin resistance but no β-cell dysfunction increased, and the proportion of participants with β-cell dysfunction but no insulin resistance decreased as body mass index (BMI) increased. People diagnosed with diabetes before 40 years of age had significantly higher HOMA-IR and BMI than those diagnosed over 65 years of age (HOMA-IR, 5.0 vs. 3.0; BMI, 28.7 kg/m2 vs. 25.1 kg/m2). However, the β-cell function indices were lower in people diagnosed before 40 years of age than in those diagnosed after 65 years of age (homeostatic model assessment of β-cell function, 39.3 vs. 64.9; insulinogenic index, 10.3 vs. 18.7; disposition index, 0.15 vs. 0.25). ConclusionWe observed that the main pathogenic mechanism of type 2 diabetes is insulin resistance in participants with newly diagnosed type 2 diabetes. In addition, young adults with diabetes are more likely to have higher insulin resistance with obesity and have higher insulin secretory defect with severe hyperglycemia in the early period of diabetes than older populations.
-
Citations
Citations to this article as recorded by
- Comparison of β-Cell Function and Insulin Sensitivity Between Normal-Weight and Obese Chinese With Young-Onset Type 2 Diabetes
Yingnan Fan, Elaine Chow, Cadmon K.P. Lim, Yong Hou, Sandra T.F. Tsoi, Baoqi Fan, Eric S.H. Lau, Alice P.S. Kong, Ronald C.W. Ma, Hongjiang Wu, Juliana C.N. Chan, Andrea O.Y. Luk Diabetes.2024; 73(6): 953. CrossRef - Effects of insulin resistance and β-cell function on diabetic complications in Korean diabetic patients
Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Mohammad Reza Mahmoodi PLOS ONE.2024; 19(10): e0312439. CrossRef - A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim Diabetes, Obesity and Metabolism.2022; 24(9): 1800. CrossRef - Apparent Insulin Deficiency in an Adult African Population With New-Onset Type 2 Diabetes
Davis Kibirige, Isaac Sekitoleko, Priscilla Balungi, William Lumu, Moffat J. Nyirenda Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef - Rising Incidence of Diabetes in Young Adults in South Korea: A National Cohort Study
Hyun Ho Choi, Giwoong Choi, Hojun Yoon, Kyoung Hwa Ha, Dae Jung Kim Diabetes & Metabolism Journal.2022; 46(5): 803. CrossRef - A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y Diabetes & Metabolism Journal.2022; 46(6): 855. CrossRef - The Potential Effect of Rhizoma coptidis on Polycystic Ovary Syndrome Based on Network Pharmacology and Molecular Docking
Liyun Duan, De Jin, Xuedong An, Yuehong Zhang, Shenghui Zhao, Rongrong Zhou, Yingying Duan, Yuqing Zhang, Xinmin Liu, Fengmei Lian, Wen yi Kang Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1. CrossRef - PRKAA2variation and the clinical characteristics of patients newly diagnosed with type 2 diabetes mellitus in Yogyakarta, Indonesia
Dita Maria Virginia, Mae Sri Hartati Wahyuningsih, Dwi Aris Agung Nugrahaningsih Asian Biomedicine.2021; 15(4): 161. CrossRef - Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim Diabetes & Metabolism Journal.2020; 44(1): 67. CrossRef - Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung Endocrinology and Metabolism.2019; 34(4): 382. CrossRef - Insulin Resistance versus β-Cell Failure: Is It Changing in Koreans?
Mi-kyung Kim Diabetes & Metabolism Journal.2018; 42(2): 128. CrossRef - Response: Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index (Diabetes Metab J2018;42:137-46)
Kyoung Hwa Ha, Dae Jung Kim, Sungrae Kim Diabetes & Metabolism Journal.2018; 42(3): 251. CrossRef - Letter: Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index (Diabetes Metab J 2018;42:137-46)
Ah Reum Khang Diabetes & Metabolism Journal.2018; 42(3): 249. CrossRef
- Others
- Clinical Implications of Using Post-Challenge Plasma Glucose Levels for Early Diagnosis of Type 2 Diabetes Mellitus in Older Individuals
-
Kyong Hye Joung, Sang Hyun Ju, Ji Min Kim, Sorim Choung, Jae Min Lee, Kang Seo Park, Hyun Jin Kim, Bon Jeong Ku
-
Diabetes Metab J. 2018;42(2):147-154. Published online February 13, 2018
-
DOI: https://doi.org/10.4093/dmj.2018.42.2.147
-
-
5,408
View
-
43
Download
-
5
Web of Science
-
4
Crossref
-
Abstract
PDFPubReader
- Background
The aim of this study was to explore the differences in the clinical characteristics and diagnostic rates of diabetes mellitus (DM) according to various criteria in different age groups and to evaluate the efficacy of each criterion for screening older patients. MethodsWe studied 515 patients and measured the fasting plasma glucose level (FPG), 2-hour plasma glucose level after the 75 g oral glucose tolerance test (2-hour postload glucose [2-h PG]), and glycosylated hemoglobin (HbA1c) for re-evaluation of hyperglycemia without a history of diabetes. Patients with newly diagnosed DM were grouped by age as younger (<65 years) or older (≥65 years). ResultsOlder patients had significantly lower HbA1c, FPG, and 2-h PG levels and a higher homeostatic level of pancreatic β-cell function compared with younger patients (P<0.001). The older group had the lowest diagnostic rate when using the FPG level (45.5%) and the highest diagnostic rate when using the 2-h PG level (84.6%). These results were mostly due to the higher frequency of isolated post-challenge hyperglycemia in the older patients than in the younger group (28.8% vs. 9.2%). The use of both the FPG and HbA1c levels significantly enhanced the low diagnostic power when employing only the FPG levels in the older group (71.2% vs. 45.5%). ConclusionIn the older patients, the 2-h PG level was the most accurate diagnostic criterion. When we consider the costs and convenience, a combination of the FPG and HbA1c criteria may be recommended as a screening test for DM in older people.
-
Citations
Citations to this article as recorded by
- International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes
Michael Bergman, Melania Manco, Ilhan Satman, Juliana Chan, Maria Inês Schmidt, Giorgio Sesti, Teresa Vanessa Fiorentino, Muhammad Abdul-Ghani, Ram Jagannathan, Pramod Kumar Thyparambil Aravindakshan, Rafael Gabriel, Viswanathan Mohan, Martin Buysschaert, Diabetes Research and Clinical Practice.2024; 209: 111589. CrossRef - Development and validation of a machine learning‐based model to predict isolated post‐challenge hyperglycemia in middle‐aged and elder adults: Analysis from a multicentric study
Rui Hou, Jingtao Dou, Lijuan Wu, Xiaoyu Zhang, Changwei Li, Weiqing Wang, Zhengnan Gao, Xulei Tang, Li Yan, Qin Wan, Zuojie Luo, Guijun Qin, Lulu Chen, Jianguang Ji, Yan He, Wei Wang, Yiming Mu, Deqiang Zheng Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef - A unified technique for entropy enhancement based diabetic retinopathy detection using hybrid neural network
Fatima, Muhammad Imran, Anayat Ullah, Muhammad Arif, Rida Noor Computers in Biology and Medicine.2022; 145: 105424. CrossRef - In-silico identification of peroxisome proliferator-activated receptor (PPAR)α/γ agonists from Ligand Expo Components database
Xiao-Yan Feng, Ting-Ting Ding, Ya-Ya Liu, Wei-Ren Xu, Xian-Chao Cheng Journal of Biomolecular Structure and Dynamics.2021; 39(5): 1853. CrossRef
- Clinical Diabetes & Therapeutics
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi
-
Diabetes Metab J. 2017;41(6):423-429. Published online December 19, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.6.423
-
-
6,671
View
-
80
Download
-
5
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
-
Citations
Citations to this article as recorded by
- Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi European Journal of Pharmacology.2022; 933: 175269. CrossRef - Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv Journal of Healthcare Engineering.2021; 2021: 1. CrossRef - Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11. CrossRef - The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Ju-Ming Lu Advances in Therapy.2019; 36(4): 798. CrossRef - A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego Diabetes Therapy.2019; 10(1): 5. CrossRef - Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim The Journal of Korean Diabetes.2018; 19(1): 35. CrossRef
- Clinical Diabetes & Therapeutics
- Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
-
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
-
Diabetes Metab J. 2017;41(5):337-348. Published online October 17, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.337
-
-
8,181
View
-
84
Download
-
39
Web of Science
-
46
Crossref
-
Abstract
PDFPubReader
In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.
-
Citations
Citations to this article as recorded by
- Clinical Diabetes & Therapeutics
- Monotherapy in Patients with Type 2 Diabetes Mellitus
-
Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
-
Diabetes Metab J. 2017;41(5):349-356. Published online October 19, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.349
-
-
6,664
View
-
90
Download
-
15
Web of Science
-
16
Crossref
-
Abstract
PDFPubReader
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly.
-
Citations
Citations to this article as recorded by
- Brazil nut (Bertholletia excelsa) and metformin abrogate cardiac complication in fructose/STZ-induced type 2 diabetic rats by attenuating oxidative stress and modulating the MAPK-mTOR/NFkB/IL-10 signaling pathways
Zhenzuo Li, Baolan Wang, Dongfang Bai, Li Zhang Food & Nutrition Research.2024;[Epub] CrossRef - Metformin and vitamin D combination therapy ameliorates type 2 diabetes mellitus-induced renal injury in male Wistar rats
Halimat Amin Abdulrahim, Adeyemi Fatai Odetayo, Emmanuel Aduragbemi Owootori, Joshua Damrah Bulus, Fatimoh Bolanle Jimoh, Emmanuel Oluwamuyiwa Gabriel, Iyanu Feranmi Odiete, Luqman Aribidesi Olayaki Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub] CrossRef - A comparison of the Anti-diabetic Potential of Magnetized Water, Metformin, and Their Combination in A Rat Model of Type II Diabetes
Alaa H. Sayed, Amira S. Ahmed, Mahmoud Hozayn, Ola A. M. Mohawed, Hanaa H. Ahmed, Rehab S. Abohashem Biomedical and Pharmacology Journal.2024; 17(3): 1575. CrossRef - Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records
Haowen Hsu, Paul Thomas Kocis, Ariana Pichardo‐Lowden, Wenke Hwang Journal of Diabetes.2024;[Epub] CrossRef - Diabetic Patients with COVID-19 Complications: Insights into Prevalence,
Prognosis, Combination Medications, and Underlying Mechanisms
Pranay Wal, Jyotsana Dwivedi, Ankita Wal, Shivangi Kushwaha Current Diabetes Reviews.2023;[Epub] CrossRef - Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef - Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel α-amylase inhibitors
Amani Toumi, Sarra Boudriga, Khaled Hamden, Mansour Sobeh, Mohammed Cheurfa, Moheddine Askri, Michael Knorr, Carsten Strohmann, Lukas Brieger Bioorganic Chemistry.2021; 106: 104507. CrossRef - Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
Harmeet Kaur, Arvinder Kaur, Pankaj Kumar Prashar, Anamika Gautam, Ankita Sood, Sachin Kumar Singh, Monica Gulati, Narendra Kumar Pandey, Bimlesh Kumar Research Journal of Pharmacy and Technology.2021; : 3471. CrossRef - Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi, Amit Kumar Nayak, Anindita Behera Biomedicine & Pharmacotherapy.2020; 131: 110708. CrossRef - Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim Diabetes, Obesity and Metabolism.2020; 22(2): 173. CrossRef - Metabolomics approach to identify the active substances influencing the antidiabetic activity of Lagerstroemia species
Mun-Ock Kim, Su Ui Lee, Heung Joo Yuk, Hyun-Jae Jang, Jae-Won Lee, Eun-Bin Kwon, Jin-Hyub Paik, SangHo Choi, Adek Nizar, Tran The Bach, Kongmany Sydara, Hang Jin, So-Yeun Woo, Sei-Ryang Oh, Hyung Won Ryu Journal of Functional Foods.2020; 64: 103684. CrossRef - Cardiometabolic diseases and active aging - polypharmacy in control
Adriana Nancy Medeiros dos Santos, Dulcineia Rebecca Cappelletti Nogueira, Beatriz Aparecida Ozello Gutierrez, Rosa Yuka Sato Chubaci, Caroline Ribeiro de Borja Oliveira Revista Brasileira de Enfermagem.2020;[Epub] CrossRef - Anti-Diabetic Nephropathy Activities of Polysaccharides Obtained from Termitornyces albuminosus via Regulation of NF-κB Signaling in db/db Mice
Chang Yang, Qi Feng, Huan Liao, Xinlei Yu, Yang Liu, Di Wang International Journal of Molecular Sciences.2019; 20(20): 5205. CrossRef - Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes
Min Joo Kim, Mi Na Kim, Se Hee Min, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung Metabolism.2019; 97: 87. CrossRef - A randomized, open‐label, multicentre, parallel‐controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti
Lixin Guo, Li Chen, Baocheng Chang, Liyong Yang, Yu Liu, Bo Feng Diabetes, Obesity and Metabolism.2018; 20(12): 2740. CrossRef - Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association
Sang Youl Rhee The Journal of Korean Diabetes.2018; 19(1): 15. CrossRef
- Clinical Diabetes & Therapeutics
- Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
-
Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
-
Diabetes Metab J. 2017;41(5):357-366. Published online October 24, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.357
-
-
8,906
View
-
189
Download
-
20
Web of Science
-
17
Crossref
-
Abstract
PDFPubReader
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.
-
Citations
Citations to this article as recorded by
- Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications
Neha V. Bhilare, Rushikesh Shedge, Prashant M. Tambe, Ajinkya More Medicinal Chemistry Research.2024; 33(3): 337. CrossRef - Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data
Ariane Jullien, Clément Jambon-Barbara, Jean-Luc Cracowski, Brian L. Claggett, Anne-Laure Borel, Charles Khouri, Matthieu Roustit Diabetes Care.2024; 47(11): 1949. CrossRef - Advances in structure-hypoglycemic activity relationship and mechanisms of berry polysaccharides
Su Jiang-Peng, Fang Jia-Qin, Liu Chuang, Liu Shou-Ping, Chen Chun, Tan Chin-Ping, Wang Ping-Ping, Peng Yun-Ping, Fu Xiong Food Bioscience.2024; 62: 105472. CrossRef - Simultaneous Estimation of Repaglinide and Voglibose in Newly Approved Fixed-Dose Combination by using UFLC: Application to ICH Q14 Concept and Comparative Method Greenness Assessment
S.S. Panda, P.C. Rauta, V.S. Pulusu, S. Sahu, B.B. Dash Asian Journal of Chemistry.2023; 35(4): 887. CrossRef - Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav International Journal of Diabetes in Developing Countries.2023; 43(6): 856. CrossRef - The Gut Microbiome, Metformin, and Aging
Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li Annual Review of Pharmacology and Toxicology.2022; 62(1): 85. CrossRef - Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial
Wajiha Mahjabeen, Dilshad Ahmed Khan, Shakil Ahmed Mirza Complementary Therapies in Medicine.2022; 66: 102819. CrossRef - Letrozole: Pharmacology, toxicity and potential therapeutic effects
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Dhanushya Nagarajan, Vibhaa K K, Anagha V, Joshua Paul P, Tharani Priya T, Rituraj Chakraborty, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan Life Sciences.2022; 310: 121074. CrossRef - Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef - Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non‐interventional comparative study
Sirajudeen Shaik Alavudeen, Sultan M. Alshahrani, Easwaran Vigneshwaran, Noohu Abdulla Khan, Javid I. Mir, Abubakr T. M. Hussein International Journal of Clinical Practice.2021;[Epub] CrossRef - Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus
Antonios Kousaxidis, Anthi Petrou, Vasiliki Lavrentaki, Maria Fesatidou, Ioannis Nicolaou, Athina Geronikaki European Journal of Medicinal Chemistry.2020; 207: 112742. CrossRef - Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
Hannah Seok, Tae Seo Sohn Diabetes & Metabolism Journal.2019; 43(4): 545. CrossRef - A Survey of the Structures of US FDA Approved Combination Drugs
Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson Journal of Medicinal Chemistry.2019; 62(9): 4265. CrossRef - Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets
Marianne A. Mahrouse, Nesrine T. Lamie Microchemical Journal.2019; 147: 691. CrossRef - The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
Da Young Lee, Ji Hee Yu, Sanghyun Park, Kyungdo Han, Nam Hoon Kim, Hye Jin Yoo, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim, Ji A. Seo Scientific Reports.2018;[Epub] CrossRef - Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India
Nikhilesh Pradhan, Sidhartha Das, Anoj Kumar Baliarsinha, Ashirbad Parhi, Bijan Patnaik, Pramod Kumar Rout Journal of Diabetes Mellitus.2018; 08(02): 9. CrossRef - Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan‐Woo Lee Journal of Diabetes Investigation.2018; 9(5): 1144. CrossRef
- Clinical Diabetes & Therapeutics
- Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
-
Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
-
Diabetes Metab J. 2017;41(5):367-373. Published online October 24, 2017
-
DOI: https://doi.org/10.4093/dmj.2017.41.5.367
-
-
8,919
View
-
263
Download
-
10
Web of Science
-
11
Crossref
-
Abstract
PDFPubReader
The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.
-
Citations
Citations to this article as recorded by
- Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang Advances in Therapy.2024; 41(5): 1967. CrossRef - Exploring Folklore Ecuadorian Medicinal Plants and Their Bioactive Components Focusing on Antidiabetic Potential: An Overview
Soham Bhattacharya, Neha Gupta, Adéla Flekalová, Salomé Gordillo-Alarcón, Viviana Espinel-Jara, Eloy Fernández-Cusimamani Plants.2024; 13(11): 1436. CrossRef - 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Diabetes & Metabolism Journal.2024; 48(4): 546. CrossRef - Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee Frontiers in Endocrinology.2022;[Epub] CrossRef - Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef - Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial
Atthayaporn Choomai, Apichai Wattanapisit, Orathai Tiangtam Romanian Journal of Internal Medicine.2021; 59(2): 151. CrossRef - Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung Endocrinology and Metabolism.2019; 34(4): 382. CrossRef - Capacity and confidence building for general practitioners on optimum insulin use
Sanjay Kalra, Prasun Deb, KalyanK Gangopadhyay, Sunil Gupta, Abhay Ahluwalia Journal of Family Medicine and Primary Care.2019; 8(10): 3096. CrossRef - Educational Strategies for Insulin Injection Therapy in Elderly Diabetic Patients
Eun Chong Shin The Journal of Korean Diabetes.2018; 19(2): 101. CrossRef - Summary of Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
Byung-Wan Lee The Journal of Korean Diabetes.2018; 19(1): 31. CrossRef - New anti-diabetic agents
Doo-Man Kim Journal of the Korean Medical Association.2017; 60(12): 992. CrossRef
- Others
- Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
-
Ji Min Kim, Min Kyung Back, Hyon-Seung Yi, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku
-
Diabetes Metab J. 2016;40(1):70-78. Published online February 19, 2016
-
DOI: https://doi.org/10.4093/dmj.2016.40.1.70
-
-
4,829
View
-
50
Download
-
5
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader
- Background
Elevated serum levels of growth differentiation factor-15 (GDF-15) are associated with type 2 diabetes. Therefore, the effects of atorvastatin on metabolic parameters and GDF-15 levels in patients with type 2 diabetes and dyslipidemia were evaluated. MethodsIn this prospective randomized trial from February 2013 to March 2014, 50 consecutive type 2 diabetic patients with a low density lipoprotein cholesterol (LDL-C) levels ≥100 mg/dL were enrolled. The patients were divided into two groups based on the amount of atorvastatin prescribed, 10 mg/day (n=23) or 40 mg/day (n=27). The effect of atorvastatin on metabolic parameters, including lipid profiles and GDF-15 levels, at baseline and after 8 weeks of treatment were compared. ResultsThe baseline metabolic parameters and GDF-15 levels were not significantly different between the two groups. After 8 weeks of treatment, the total cholesterol (TC) and LDL-C levels were significantly decreased in both groups. The mean changes in TC and LDL-C levels were more significant in the 40 mg atorvastatin group. The GDF-15 level was decreased in the 10 mg atorvastatin group, from 1,460.6±874.8 to 1,451.0±770.8 pg/mL, and was increased in the 40 mg atorvastatin group, from 1,271.6±801.0 to 1,341.4±855.2 pg/mL. However, the change in the GDF-15 level was not statistically significant in the 10 or 40 mg atorvastatin group (P=0.665 and P=0.745, respectively). ConclusionThe GDF-15 levels were not significantly changed after an 8-week treatment with atorvastatin in type 2 diabetic patients.
-
Citations
Citations to this article as recorded by
- The relationship of Growth differentiation factor-15 with renal damage and dyslipidemia in non-albuminuric and albuminuric Type-2 Diabetes Mellitus
Hasan Esat Yücel, Bilal İlanbey Medical Science and Discovery.2022; 9(6): 334. CrossRef - Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis
Alexander Hodkinson, Dialechti Tsimpida, Evangelos Kontopantelis, Martin K Rutter, Mamas A Mamas, Maria Panagioti BMJ.2022; : e067731. CrossRef - The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker
Boel De Paepe International Journal of Molecular Sciences.2022; 23(21): 13180. CrossRef - Biomarkers of subclinical atherosclerosis in patients with psoriasis
Hannah Kaiser, Xing Wang, Amanda Kvist-Hansen, Martin Krakauer, Peter Michael Gørtz, Benjamin D. McCauley, Lone Skov, Christine Becker, Peter Riis Hansen Scientific Reports.2021;[Epub] CrossRef - Growth differentiation factor-15 regulates oxLDL-induced lipid homeostasis and autophagy in human macrophages
Kathrin Ackermann, Gabriel A. Bonaterra, Ralf Kinscherf, Anja Schwarz Atherosclerosis.2019; 281: 128. CrossRef
- GDF15 Is a Novel Biomarker for Impaired Fasting Glucose
-
Jun Hwa Hong, Hyo Kyun Chung, Hye Yoon Park, Kyong-Hye Joung, Ju Hee Lee, Jin Gyu Jung, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong
-
Diabetes Metab J. 2014;38(6):472-479. Published online December 15, 2014
-
DOI: https://doi.org/10.4093/dmj.2014.38.6.472
-
-
6,500
View
-
88
Download
-
73
Web of Science
-
67
Crossref
-
Abstract
PDFPubReader
- Background
Growth differentiation factor-15 (GDF15) is a protein that belongs to the transforming growth factor β superfamily. An elevated serum level of GDF15 was found to be associated with type 2 diabetes mellitus (T2DM). T2DM is an inflammatory disease that progresses from normal glucose tolerance (NGT) to impaired fasting glucose (IFG). Hence, we aimed to validate the relationship between GDF15 and IFG. MethodsThe participants were divided into the following three groups: NGT (n=137), IFG (n=29), and T2DM (n=75). The controls and T2DM outpatients visited the hospital for routine health check-ups. We used fasting blood glucose to detect IFG in nondiabetic patients. We checked the body mass index (BMI), C-reactive protein level, metabolic parameters, and fasting serum GDF15 level. ResultsAge, BMI, triglyceride, insulin, glucose, homeostatic model assessment-insulin resistance (HOMA-IR), and GDF15 levels were elevated in the IFG and T2DM groups compared to the NGT group. In the correlation analysis between metabolic parameters and GDF15, age and HOMA-IR had a significant positive correlation with GDF15 levels. GDF15 significantly discriminated between IFG and NGT, independent of age, BMI, and HOMA-IR. The serum levels of GDF15 were more elevated in men than in women. As a biomarker for IFG based on the receiver operating characteristic curve analysis, the cutoff value of GDF15 was 510 pg/mL in males and 400 pg/mL in females. ConclusionGDF15 had a positive correlation with IR independent of age and BMI, and the serum level of GDF15 was increased in the IFG and T2DM groups. GDF15 may be a novel biomarker for detecting IFG in nondiabetic patients.
-
Citations
Citations to this article as recorded by
- Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes
Michael M Richter, Mads N Thomsen, Mads J Skytte, Sasha A S Kjeldsen, Amirsalar Samkani, Jan Frystyk, Faidon Magkos, Jens J Holst, Sten Madsbad, Thure Krarup, Steen B Haugaard, Nicolai J Wewer Albrechtsen Journal of the Endocrine Society.2024;[Epub] CrossRef - Serum Growth Differentiation Factor 15 Levels Predict the Incidence of Frailty among Patients with Cardiometabolic Diseases
Kazuhito Oba, Joji Ishikawa, Yoshiaki Tamura, Yasunori Fujita, Masafumi Ito, Ai Iizuka, Yoshinori Fujiwara, Remi Kodera, Kenji Toyoshima, Yuko Chiba, Masashi Tanaka, Atsushi Araki Gerontology.2024; 70(5): 517. CrossRef - Growth differentiation factor 15 and malnutrition in older adults
Nazanin Rostami, Blanca Fabre-Estremera, Antonio Buño-Soto, José R Banegas, Fernando Rodríguez-Artalejo, Rosario Ortolá The Journal of nutrition, health and aging.2024; 28(6): 100230. CrossRef - Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly
Busra Firlatan, Ugur Nadir Karakulak, Vedat Hekimsoy, Burcin Gonul Iremli, Incilay Lay, Deniz Yuce, Selcuk Dagdelen, Giray Kabakci, Tomris Erbas Hormones.2024; 23(4): 777. CrossRef - Nausea, vomiting and conflict in pregnancy
Bernard J Crespi Evolution, Medicine, and Public Health.2024; 12(1): 75. CrossRef - Correlations between growth differentiation factor 15 (GDF-15) serum levels and gene polymorphism with type 2 diabetes mellitus
Qiumei Liu, Lidong Qin, Yujian Liang, Min Xu, Junling Zhang, Xiaoting Mo, Xu Tang, Yufu Lu, Xuexiu Wang, Jiejing Cao, Chuwu Huang, Jiahui Rong, Kaisheng Teng, Linhai Zhao, Songju Wu, Lei Luo, Qinyi Guan, TianTian Zhang, Wenjia Jin, Jian Qin, Jiansheng Cai Heliyon.2024; 10(12): e33044. CrossRef - Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus
Carlijn A. Hoekx, Maaike E. Straat, Maurice B. Bizino, Huub J. van Eyk, Hildebrandus J. Lamb, Johannes W. A. Smit, Ingrid M. Jazet, Saskia C. A. de Jager, Mariëtte R. Boon, Borja Martinez‐Tellez Experimental Physiology.2024; 109(8): 1292. CrossRef - GDF-15 and mtDNA Deletions Are Useful Biomarkers of Mitochondrial Dysfunction in Insulin Resistance and PCOS
Vera Varhegyi, Anna Modos, Domonkos Trager, Dora Gerszi, Eszter Maria Horvath, Miklos Sipos, Nandor Acs, Maria Judit Molnar, Szabolcs Varbiro, Aniko Gal International Journal of Molecular Sciences.2024; 25(20): 10916. CrossRef - Exploration of meteorin-like peptide (metrnl) predictors in type 2 diabetic patients: the potential role of irisin, and other biochemical parameters
Yaser Khajebishak, Amir Hossein Faghfouri, Ali Soleimani, Sadra Madani, Laleh Payahoo Hormone Molecular Biology and Clinical Investigation.2023; 44(2): 127. CrossRef - Relationship between meteorin-like peptide (Metrnl) serum levels and inflammatory cytokines, oxidative stress biomarkers and body composition parameters in type 2 diabetes patients
Yaser Khajebishak, Sadra Madani, Amir Hossein Faghfouri, Ali Soleimani, Sara Ilaei, Said Peyrovi, Laleh Payahoo Nutrition & Food Science.2023; 53(5): 861. CrossRef - Effects of acute exercise and exercise training on plasma GDF15 concentrations and associations with appetite and cardiometabolic health in individuals with overweight or obesity – A secondary analysis of a randomized controlled trial
Jonas Salling Quist, Anders Bue Klein, Kristine Færch, Kristine Beaulieu, Mads Rosenkilde, Anne Sofie Gram, Anders Sjödin, Signe Torekov, Bente Stallknecht, Christoffer Clemmensen, Martin Bæk Blond Appetite.2023; 182: 106423. CrossRef - Significant increase of serum extracellular vesicle-packaged growth differentiation factor 15 in type 2 diabetes mellitus: a cross-sectional study
Wen Zhao, Xinwei Li, Xinxin Li, Lu Peng, Yu Li, Yunhui Du, Jianxun He, Yanwen Qin, Huina Zhang European Journal of Medical Research.2023;[Epub] CrossRef - Association between growth differentiation factor 15 levels and gestational diabetes mellitus: A combined analysis
Yi-Cheng Lu, Song-Liang Liu, Yu-Shan Zhang, Fei Liang, Xiao-Yan Zhu, Yue Xiao, Jing Wang, Cong Ding, Sudipta Banerjee, Jie-Yun Yin, Qiu-Ping Ma Frontiers in Endocrinology.2023;[Epub] CrossRef - Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight
Song-Yang Zhang, Kyla Bruce, Zahra Danaei, Rosa J.W. Li, Daniel R. Barros, Rachel Kuah, Yu-Mi Lim, Laura H. Mariani, David Z. Cherney, Jennifer F.M. Chiu, Heather N. Reich, Tony K.T. Lam Cell Metabolism.2023; 35(5): 875. CrossRef - Growth differentiation factor 15 (GDF-15) in endocrinology
Pedro Iglesias, Ramona A. Silvestre, Juan J. Díez Endocrine.2023; 81(3): 419. CrossRef - Identification of biomarkers for glycaemic deterioration in type 2 diabetes
Roderick C. Slieker, Louise A. Donnelly, Elina Akalestou, Livia Lopez-Noriega, Rana Melhem, Ayşim Güneş, Frederic Abou Azar, Alexander Efanov, Eleni Georgiadou, Hermine Muniangi-Muhitu, Mahsa Sheikh, Giuseppe N. Giordano, Mikael Åkerlund, Emma Ahlqvist, A Nature Communications.2023;[Epub] CrossRef - Metabolic syndrome and Growth Differentiation Factor 15 in older adults
Adrián Carballo-Casla, Esther García-Esquinas, Antonio Buño-Soto, Ellen A. Struijk, Esther López-García, Fernando Rodríguez-Artalejo, Rosario Ortolá GeroScience.2022; 44(2): 867. CrossRef - Associations between GDF15 Levels and Pre-Diabetes in Non-Obese Subjects
Hao-Chang Hung, Hung-Tsung Wu, Ching-Han Lin, Hsuan-Wen Chou, Horng-Yih Ou, Chih-Jen Chang Journal of Investigative Medicine.2022; 70(1): 79. CrossRef - Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Dipayan Roy, Purvi Purohit, Anupama Modi, Manoj Khokhar, Ravindra Kumar Gayaprasad Shukla, Ramkaran Chaudhary, Shrimanjunath Sankanagoudar, Praveen Sharma Current Diabetes Reviews.2022;[Epub] CrossRef - Growth Differentiation Factor 15 Protects SH-SY5Y Cells From Rotenone-Induced Toxicity by Suppressing Mitochondrial Apoptosis
Peizheng Li, Hongbo Lv, Bohan Zhang, Ruonan Duan, Xiufang Zhang, Pengfei Lin, Chengyuan Song, Yiming Liu Frontiers in Aging Neuroscience.2022;[Epub] CrossRef - GDF-15 as a Therapeutic Target of Diabetic Complications Increases the Risk of Gallstone Disease: Mendelian Randomization and Polygenic Risk Score Analysis
Lili Yu, Yajing Zhou, Lijuan Wang, Xuan Zhou, Jing Sun, Jiarui Xiao, Xiaolin Xu, Susanna C. Larsson, Shuai Yuan, Xue Li Frontiers in Genetics.2022;[Epub] CrossRef - Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity
Mohamed Asrih, Flore Sinturel, Richard Dubos, Idris Guessous, Zoltan Pataky, Charna Dibner, François R Jornayvaz, Karim Gariani Endocrine Connections.2022;[Epub] CrossRef - Raised circulating soluble growth differentiation factor 15 is negatively associated with testosterone level in hypogonadic men with type 2 diabetes
Yufeng Mei, Yongnan Lyu, Juan Le, Di Li, Hang Liu, Zhiming Zhao, Yan Li Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef - NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice
Matthew J Jennings, Alexia Kagiava, Leen Vendredy, Emily L Spaulding, Marina Stavrou, Denisa Hathazi, Anika Grüneboom, Vicky De Winter, Burkhard Gess, Ulrike Schara, Oksana Pogoryelova, Hanns Lochmüller, Christoph H Borchers, Andreas Roos, Robert W Burges Brain.2022; 145(11): 3999. CrossRef - Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Athanasios Alexiou, Marios Papadakis, Eman Hassan Nadwa, Sarah M. Albogami, Mohammed Alorabi, Hebatallah M. Saad, Gaber El‐Saber Batiha Journal of Diabetes.2022; 14(12): 806. CrossRef - GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans
Peter Plomgaard, Jakob S. Hansen, Logan K. Townsend, Anders Gudiksen, Niels H. Secher, Jens O. Clemmesen, Rene K. Støving, Jens P. Goetze, David C. Wright, Henriette Pilegaard Frontiers in Endocrinology.2022;[Epub] CrossRef - A study of serum growth differentiation factor 15 in Indian women with and without gestational diabetes mellitus in the third trimester of pregnancy and its association with pro-inflammatory markers and glucose metabolism
Sudipta Banerjee, Rana Bhattacharjee, Amitabh Sur, Pieu Adhikary, Subhankar Chowdhury Diabetology International.2021; 12(3): 254. CrossRef - Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness
Yea Eun Kang, Jin Man Kim, Mi Ae Lim, Seong Eun Lee, Shinae Yi, Jung Tae Kim, Chan Oh, Lihua Liu, Yanli Jin, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Jeong Ho Lee, Hyun Jung Kim, Hyun Yong Koh, Sangmi Jun, Sun Wook Cho, Minho Shong, Bon Seok Koo Thyroid.2021; 31(5): 772. CrossRef - The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
Samuel N. Breit, David A. Brown, Vicky Wang-Wei Tsai Annual Review of Physiology.2021; 83(1): 127. CrossRef - Associations of GDF-15 and GDF-15/adiponectin ratio with odds of type 2 diabetes in the Chinese population
Xiaoying Wu, Wenting Xuan, Lili You, Hong Lian, Feng Li, Xiaoyun Zhang, Qingyu Chen, Kan Sun, Chaogang Chen, Mingtong Xu, Yan Li, Li Yan, Xiuwei Zhang, Meng Ren Endocrine.2021; 72(2): 423. CrossRef - Decreased serum growth differentiation factor 15 levels after lifestyle intervention in patients with newly diagnosed type 2 diabetes mellitus
Xingxing He, Jiaorong Su, Xiaojing Ma, Jingyi Lu, Yufei Wang, Jun Yin, Yuqian Bao, Gang Hu, Jian Zhou Obesity Medicine.2021; 24: 100345. CrossRef - The anti-diabetic effects of NAG-1/GDF15 on HFD/STZ-induced mice
Pattawika Lertpatipanpong, Jaehak Lee, Ilju Kim, Thomas Eling, Seung Yeon Oh, Je Kyung Seong, Seung Joon Baek Scientific Reports.2021;[Epub] CrossRef - The Regulation of Circulating Hepatokines by Fructose Ingestion in Humans
Michael M Richter, Peter Plomgaard Journal of the Endocrine Society.2021;[Epub] CrossRef - GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Dongdong Wang, Emily A. Day, Logan K. Townsend, Djordje Djordjevic, Sebastian Beck Jørgensen, Gregory R. Steinberg Nature Reviews Endocrinology.2021; 17(10): 592. CrossRef - High Fat, High Sugar Diet and DJOS Bariatric Surgery Influence Plasma Levels of Fetuin-B, Growth Differentiation Factor-15, and Pentraxin 3 in Diet-Induced Obese Sprague–Dawley Rats
Jakub Poloczek, Monika Tarnawska, Elżbieta Chełmecka, Piotr Łaszczyca, Janusz Gumprecht, Dominika Stygar Nutrients.2021; 13(10): 3632. CrossRef - Serum growth differentiation factor 15 level is associated with muscle strength and lower extremity function in older patients with cardiometabolic disease
Kazuhito Oba, Joji Ishikawa, Yoshiaki Tamura, Yasunori Fujita, Masafumi Ito, Ai Iizuka, Yoshinori Fujiwara, Remi Kodera, Ayumi Toba, Kenji Toyoshima, Yuko Chiba, Seijiro Mori, Masashi Tanaka, Hideki Ito, Kazumasa Harada, Atsushi Araki Geriatrics & Gerontology International.2020; 20(10): 980. CrossRef - Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach
Axel C. Carlsson, Christoph Nowak, Lars Lind, Carl Johan Östgren, Fredrik H. Nyström, Johan Sundström, Juan Jesus Carrero, Ulf Riserus, Erik Ingelsson, Tove Fall, Johan Ärnlöv Upsala Journal of Medical Sciences.2020; 125(1): 37. CrossRef - Elevated Plasma Growth and Differentiation Factor 15 Is Associated With Slower Gait Speed and Lower Physical Performance in Healthy Community-Dwelling Adults
Richard D Semba, Marta Gonzalez-Freire, Toshiko Tanaka, Angelique Biancotto, Pingbo Zhang, Michelle Shardell, Ruin Moaddel, Luigi Ferrucci, Anne Newman The Journals of Gerontology: Series A.2020; 75(1): 175. CrossRef - Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review
Alexander E. Berezin, Alexander A. Berezin Diabetes Therapy.2020; 11(6): 1271. CrossRef - Deterioration of Sleep Quality According to Glycemic Status
Myung Haeng Hur, Mi-Kyoung Lee, Kayeon Seong, Jun Hwa Hong Diabetes & Metabolism Journal.2020; 44(5): 679. CrossRef - Effects of plant and animal high protein diets on immune-inflammatory biomarkers: A 6-week intervention trial
Mariya Markova, Liselot Koelman, Silke Hornemann, Olga Pivovarova, Stephanie Sucher, Juergen Machann, Natalia Rudovich, Ralph Thomann, Rosemarie Schneeweiss, Sascha Rohn, Andreas F.H. Pfeiffer, Krasimira Aleksandrova Clinical Nutrition.2020; 39(3): 862. CrossRef - Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human
Ponnie Robertlee Dolo, Libin Yao, Peng Peng Liu, Jason Widjaja, Song Meng, Chao Li, Xiaocheng Zhu The American Journal of Surgery.2020; 220(3): 725. CrossRef - Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers
Alexander E. Berezin Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 995. CrossRef - Effect of bariatric surgery on plasma GDF15 in humans
Maximilian Kleinert, Kirstine N. Bojsen-Møller, Nils B. Jørgensen, Maria S. Svane, Christoffer Martinussen, Bente Kiens, Jørgen F.P. Wojtaszewski, Sten Madsbad, Erik A. Richter, Christoffer Clemmensen American Journal of Physiology-Endocrinology and Metabolism.2019; 316(4): E615. CrossRef - Regulation of Systemic Glucose Homeostasis by T Helper Type 2 Cytokines
Yea Eun Kang, Hyun Jin Kim, Minho Shong Diabetes & Metabolism Journal.2019; 43(5): 549. CrossRef - GDF15 reflects beta cell function in obese patients independently of the grade of impairment of glucose metabolism
M.H. Schernthaner-Reiter, B.K. Itariu, M. Krebs, M. Promintzer-Schifferl, T.M. Stulnig, A. Tura, C.H. Anderwald, M. Clodi, B. Ludvik, G. Pacini, A. Luger, G. Vila Nutrition, Metabolism and Cardiovascular Diseases.2019; 29(4): 334. CrossRef - Growth differentiation factor 15: A novel biomarker with high clinical potential
Stéphanie Desmedt, Valérie Desmedt, Leen De Vos, Joris R. Delanghe, Reinhart Speeckaert, Marijn M. Speeckaert Critical Reviews in Clinical Laboratory Sciences.2019; 56(5): 333. CrossRef - Hepatokines—a novel group of exercise factors
Cora Weigert, Miriam Hoene, Peter Plomgaard Pflügers Archiv - European Journal of Physiology.2019; 471(3): 383. CrossRef - Association between MIC-1 and Type 2 Diabetes: A Combined Analysis
Jianan Lu, Yue Zhang, Xingxuan Dong, Jiawen Lu, Chen Zhang, Jieyu Liu, Qingzhou Yu, Haoyue Teng, Qingkui Yao, Jieyun Yin, Liqiang Qin Disease Markers.2019; 2019: 1. CrossRef - The mitochondrial unfolded protein response and mitohormesis: a perspective on metabolic diseases
Hyon-Seung Yi, Joon Young Chang, Minho Shong Journal of Molecular Endocrinology.2018; 61(3): R91. CrossRef - Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases
Ana Luisa Cardoso, Adelaide Fernandes, Juan Antonio Aguilar-Pimentel, Martin Hrabě de Angelis, Joana Ribeiro Guedes, Maria Alexandra Brito, Saida Ortolano, Giovambattista Pani, Sophia Athanasopoulou, Efstathios S. Gonos, Markus Schosserer, Johannes Grilla Ageing Research Reviews.2018; 47: 214. CrossRef - Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes
Ju Hee Lee, Yea Eun Kang, Ji Min Kim, Sorim Choung, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku Diabetes Research and Clinical Practice.2018; 135: 7. CrossRef - Growth differentiation factor 15 predicts advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease
Bo Kyung Koo, Sung Hee Um, Dong Soo Seo, Sae Kyung Joo, Jeong Mo Bae, Jeong Hwan Park, Mee Soo Chang, Jung Ho Kim, Jieun Lee, Won‐Il Jeong, Won Kim Liver International.2018; 38(4): 695. CrossRef - Serum Growth Differentiation Factor 15 in Parkinson Disease
Xiaomei Yao, Dong Wang, Lei Zhang, Lingling Wang, Zhenxiang Zhao, Si Chen, Xiaotang Wang, Tao Yue, Yiming Liu Neurodegenerative Diseases.2017; 17(6): 251. CrossRef - GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury
Hyo Kyun Chung, Jung Tae Kim, Hyeon-Woo Kim, Minjoo Kwon, So Yeon Kim, Minho Shong, Koon Soon Kim, Hyon-Seung Yi Scientific Reports.2017;[Epub] CrossRef - Growth differentiation factor 15 as a predictor of adverse renal outcomes in patients with immunoglobulin A nephropathy
Ki R. Na, Yoo H. Kim, Hyo K. Chung, Min‐Kyung Yeo, Young R. Ham, Jin Y. Jeong, Koon S. Kim, Kang W. Lee, Dae E. Choi Internal Medicine Journal.2017; 47(12): 1393. CrossRef - GDF15 contributes to radiation-induced senescence through the ROS-mediated p16 pathway in human endothelial cells
Hyejin Park, Chun-Ho Kim, Jae-Hoon Jeong, Myungjin Park, Kwang Seok Kim Oncotarget.2016; 7(9): 9634. CrossRef - GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance
Mehmet Muhittin Yalcin, Alev Eroglu Altinova, Mujde Akturk, Ozlem Gulbahar, Emre Arslan, Damla Ors Sendogan, Ilhan Yetkin, Fusun Balos Toruner Journal of Diabetes Research.2016; 2016: 1. CrossRef - Cardiac‐Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers
Colleen M. Dewey, Kathryn M. Spitler, Jessica M. Ponce, Duane D. Hall, Chad E. Grueter Journal of the American Heart Association.2016;[Epub] CrossRef - Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study
Serdar Farhan, Matthias K. Freynhofer, Ivan Brozovic, Veronika Bruno, Birgit Vogel, Ioannis Tentzeris, Sabina Baumgartner-Parzer, Kurt Huber, Alexandra Kautzky-Willer Cardiovascular Diabetology.2016;[Epub] CrossRef - Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
Ji Min Kim, Min Kyung Back, Hyon-Seung Yi, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku Diabetes & Metabolism Journal.2016; 40(1): 70. CrossRef - Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Min Young Shin, Ji Min Kim, Yea Eun Kang, Min Kyeong Kim, Kyong Hye Joung, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong Journal of Korean Medical Science.2016; 31(9): 1413. CrossRef - Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose
Ying Cui, Wen Chen, Jinfeng Chi, Lei Wang Medical Science Monitor.2016; 22: 4699. CrossRef - Letter: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
Bo Kyung Koo Diabetes & Metabolism Journal.2015; 39(1): 82. CrossRef - Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment
Jun Hwa Hong, Yeon-Kyung Choi, Byong-Keol Min, Kang Seo Park, Kayeon Seong, In Kyu Lee, Jung Guk Kim Diabetes Research and Clinical Practice.2015; 109(1): 64. CrossRef - Response: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
Jun Hwa Hong, Bon Jeong Ku, Minho Shong Diabetes & Metabolism Journal.2015; 39(1): 84. CrossRef - Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?
Kyu Yeon Hur Diabetes & Metabolism Journal.2014; 38(6): 437. CrossRef
- Bone Mineral Density in Prediabetic Men
-
Ju Hee Lee, Yun Hyeong Lee, Kyoung Hye Jung, Min Kyeong Kim, Hye Won Jang, Tae Kyun Kim, Hyun Jin Kim, Young Suk Jo, Minho Shong, Tae Yong Lee, Bon Jeong Ku
-
Korean Diabetes J. 2010;34(5):294-302. Published online October 31, 2010
-
DOI: https://doi.org/10.4093/kdj.2010.34.5.294
-
-
5,002
View
-
32
Download
-
13
Crossref
-
Abstract
PDFPubReader
- Background
There are many studies regarding the effects of insulin on bone metabolism and changes in bone mineral density (BMD) in the setting of diabetes. The effect of prediabetes on BMD is not known. MethodsA total of 802 men participated in the Korea Rural Genomic Cohort Study (in Geumsan County). According to the results of an oral glucose tolerance test, subjects were classified into normal, prediabetic, and diabetic categories. One hundred twenty-four subjects diagnosed with type 2 diabetes were excluded, leaving 678 subjects for the study inclusion. BMD was estimated with a quantitative ultrasonometer. ResultsThe average BMD T scores of normal and prediabetic subjects were -1.34 ± 1.42 and -1.33 ± 1.30, respectively; there was no significant difference in the BMD T scores between these groups. The BMD T score was inversely associated with age and positively correlated with body weight, body mass index, total cholesterol, low density lipoprotein cholesterol, and HbA1c. On multiple linear regression analysis, low density lipoprotein cholesterol was the only statistically significant variable for prediabetes (β = 0.007, P = 0.005). On the stepwise regression analysis, age (β = -0.026, P < 0.001), the body mass index (β = 0.079, P < 0.001), and low density lipoprotein cholesterol (β = 0.004, P = 0.016) were significant variables for prediabetes. ConclusionsThere was no significant difference in the BMD T score between the normal and prediabetic subjects. Further studies are needed regarding the association of fracture risk and changes in BMD with the development of overt diabetes.
-
Citations
Citations to this article as recorded by
- More Rapid Bone Mineral Density Loss in Older Men With Diabetes: The Osteoporotic Fractures in Men (MrOS) Study
Flavia Tramontana, Nicola Napoli, Stephanie Litwack-Harrison, Douglas C Bauer, Eric S Orwoll, Jane A Cauley, Elsa S Strotmeyer, Ann V Schwartz The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2283. CrossRef - Scientometric analysis of global publications on prediabetes and osteoporosis: 1994–2023
Raju Vaishya, Brij Mohan Gupta, Ghouse Modin Nabeesab Mamdapur, Anoop Misra, Abhishek Vaish Journal of Clinical Orthopaedics and Trauma.2024; 54: 102493. CrossRef - Prediabetes and skeletal health
Catherine Lindsay, Albert Shieh Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(4): 200. CrossRef - Serum levels of sclerostin in prediabetes and its correlation with bone mineral density
Ajay Chauhan, Manoj Kumar Bhakhar, Parul Goyal Journal of Family Medicine and Primary Care.2023; 12(11): 2702. CrossRef - The risk of hip fractures in individuals over 50 years old with prediabetes and type 2 diabetes – A longitudinal nationwide population-based study
Ho Youn Park, Kyoungdo Han, Youngwoo Kim, Yoon Hwan Kim, Yoo Joon Sur Bone.2021; 142: 115691. CrossRef - Bone health in diabetes and prediabetes
Silvia Costantini, Caterina Conte World Journal of Diabetes.2019; 10(8): 421. CrossRef - Bone mineral density in obese children with prediabetes
Ala ÜSTYOL, Mehmet Emre ATABEK Ege Tıp Dergisi.2018; 57(2): 94. CrossRef - The Prevalence of Osteopenia and Osteoporosis Among Malaysian Type 2 Diabetic Patients Using Quantitative Ultrasound Densitometer
Shaymaa Abdalwahed Abdulameer, Mohanad Naji Sahib, Syed Azhar Syed Sulaiman The Open Rheumatology Journal.2018; 12(1): 50. CrossRef - An association between bone mineral density and anabolic hormones in middle-aged and elderly men with prediabetes
Michał Rabijewski, Lucyna Papierska, Paweł Piątkiewicz The Aging Male.2017; : 1. CrossRef - Amplification of transcutaneous and percutaneous bone-conduction devices with a test-band in an induced model of conductive hearing loss
Marn Joon Park, Jae Ryung Lee, Chan Joo Yang, Myung Hoon Yoo, In Suk Jin, Chi Ho Choi, Hong Ju Park International Journal of Audiology.2016; 55(11): 653. CrossRef - Osteoporosis in Men with Diabetes Mellitus
Claire Issa, Mira S. Zantout, Sami T. Azar Journal of Osteoporosis.2011; 2011: 1. CrossRef - Response: Bone Mineral Density in Prediabetic Men (Korean Diabetes J 2010;34:294-302)
Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku Korean Diabetes Journal.2010; 34(6): 386. CrossRef - Letter: Bone Mineral Density in Prediabetic Men (Korean Diabetes J 2010;34:294-302)
Chul-Hee Kim Korean Diabetes Journal.2010; 34(6): 384. CrossRef
- The Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
-
Hee-Jung Ahn, Yu-Kyung Eom, Kyung-Ah Han, Hwi-Ryun Kwon, Hyun Jin Kim, Kang Seo Park, Kyung-Wan Min
-
Korean Diabetes J. 2010;34(3):166-173. Published online June 30, 2010
-
DOI: https://doi.org/10.4093/kdj.2010.34.3.166
-
-
3,924
View
-
36
Download
-
4
Crossref
-
Abstract
PDFPubReader
- Background
The main source of carbohydrate in the Korean diet is rice, which is usually served in a rice bowl. This study investigated the impact of a meal plan using smaller rice bowls on dietary energy intake and macronutrient composition in overweight or obese patients with type 2 diabetes mellitus. MethodsA total of 67 women with type 2 diabetes were enrolled in our study. We divided these participants into three groups: a normal-weight group (NW; body mass index [BMI] < 23 kg/m2; n = 17), an overweight group (OW; 23 ≤ BMI < 25 kg/m2; n = 24) and an obese group (OB; BMI ≥ 25 kg/m2; n = 26). Three-day dietary records were analyzed for total energy intake (TEI) and macronutrient composition both before enrollment and two weeks after patients received instruction in a dietary plan based on using a small (200 mL) rice bowl. ResultsAfter the intervention, TEI decreased in the OW and OB groups. Decreased carbohydrate (NW, -4 ± 5%; OW, -4 ± 5%; OB, -3 ± 6%) and increased fat intakes were found in all three groups, which complies with Korean Diabetes Association recommendations. The protein proportion of TEI significantly increased only in the OW group. Body weight decreased both in the OW and OB groups. ConclusionA short-term, small-rice-bowl-based meal plan was effective for body weight control and macronutrient balance in overweight or obese women in Korea with type 2 diabetes.
-
Citations
Citations to this article as recorded by
- Diet Therapy Using a Small Rice Bowl among Japanese Men with Diabetes: A Randomized Controlled Trial
Misa Shimpo, Shiori Toga-Sato, Takahiro Tosaki Journal of Obesity & Metabolic Syndrome.2022; 31(4): 345. CrossRef - A traditional Asian diet modified to meet nutritional requirements of diabetes, has anything changed? A cross-sectional dietary survey
Arjuna Medagama, Heshan Widanapathirana BMC Nutrition.2015;[Epub] CrossRef - Relationship between Milk and Calcium Intake and Lipid Metabolism in Female Patients with Type 2 Diabetes
JaeHee Kim, Ji-Yun Hwang, Ki Nam Kim, Young-Ju Choi, Namsoo Chang, Kap-Bum Huh Yonsei Medical Journal.2013; 54(3): 626. CrossRef - The Small Rice Bowl-Based Meal Plan was Effective at Reducing Dietary Energy Intake, Body Weight, and Blood Glucose Levels in Korean Women with Type 2 Diabetes Mellitus
Hee Jung Ahn, Kyung Ah Han, Hwi Ryun Kwon, Kyung Wan Min Korean Diabetes Journal.2010; 34(6): 340. CrossRef
|